Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Radar On Market Access: Study Shows Growing IL-17 Use in Psoriasis

Posted by Angela Maas on Oct 15, 2019

For many years, the psoriasis treatment landscape was dominated by tumor necrosis factor (TNF) inhibitors. But with the FDA's approval of three interleukin-17 (IL-17) inhibitors — as well as other drugs with different mechanisms of action — for the condition, those therapies are becoming more common among treatment regimens, AIS Health reported.

The first IL-17 inhibitor on the U.S. market was Cosentyx (secukinumab) from Novartis Pharmaceuticals Corp., which launched in 2015. The next therapy was Taltz (ixekizumab) from Eli Lilly and Co., and then on Feb. 15, 2017, the agency approved Siliq (brodalumab) from Ortho Dermatologics.

Read More

Topics: Specialty, Market Access, Product Release, Provider, Payer

Radar On Market Access: PhRMA, Conservatives Criticize Pelosi Drug Pricing Legislation

Posted by Lauren Flynn Kelly on Oct 10, 2019

Although there is bipartisan support for drug pricing reform and recent bills introduced in the House and the Senate share some concepts, conservatives and pharmaceutical manufacturers have found plenty to dislike about the drug pricing legislation unveiled in September by House Speaker Nancy Pelosi (D-Calif.), AIS Health reported.

In addition to restructuring the Part D benefit to include an out-of-pocket cap, the Lower Drug Costs Now Act (H.R. 3) would allow the HHS secretary to negotiate drug prices for at least 250 drugs where there is no effective competition. Manufacturers would be subject to certain transparency requirements and a "noncompliance fee." Moreover, the bill would require that the negotiated price should be no more than 1.2 times the weighted average of the price in six other countries.
 
Read More

Topics: Industry Trends, Provider, Payer

Radar On Market Access: CMS Projects Record-High Medicare Advantage Enrollment in 2020

Posted by Lauren Flynn Kelly on Oct 8, 2019

2020 is shaping up to be another competitive year for the Medicare Advantage program, which will feature an additional 600 plan choices and a continued decline in the average monthly premium, AIS Health reported. With its annual release of the so-called landscape files for the MA and Part D programs, CMS on Sept. 24 said it expects MA enrollment to reach an all-time high of 24.4 million in 2020, up 10% from the current enrollment of 22.2 million.

For 2020, the average monthly MA plan premium will drop by 14% to an estimated $23, the lowest average monthly premium since 2007. As the Affordable Care Act health insurer fee (HIF) returns in 2020, CMS's bullish enrollment outlook "indicates most plans are prioritizing stability of benefits and enrollment," observed securities analyst Michael Newshel in a Sept. 24 research note from Evercore ISI.
 
Read More

Topics: Industry Trends, Data & Analytics, Provider, Payer

Perspectives on Changes to Addiction Treatment Privacy Rules

Posted by Leslie Small on Oct 3, 2019

A recent federal proposal — which would loosen privacy rules surrounding substance use disorder (SUD) treatment — is being applauded by health insurer trade groups. But some advocates are worried about potential harms to patients, AIS Health reported.

At the center of the debate is legislation enacted in the 1970s and the subsequent regulations implementing that law, known as 42 CFR Part 2, which was designed to protect the confidentiality of SUD patient records created by federally funded treatment programs. Under the proposed changes to 42 CFR Part 2, opioid treatment programs would be able to enroll in state prescription drug monitoring programs and submit the dispensing data for controlled substances consistent with applicable state laws. SUD patients also would be able to consent to disclosure of their Part 2 treatment records to an entity, without having to name a specific person.
 
Read More

Topics: Industry Trends, Provider, Payer

Radar On Market Access: Despite Approval of New Parkinson's Drugs, Plans Still Prefer Generics

Posted by Jane Anderson on Oct 3, 2019

Although three new drugs for Parkinson's disease have been approved over the last year, plans generally are sticking with the drugs they've included on formularies for several years, most of which are generic, experts tell AIS Health.

That may change in the long term as new gene therapies that currently are in development are approved and come online. But none of those potential new treatments are close to market right now, says Mesfin Tegenu, R.Ph., president of PerformRx.

Read More

Topics: Specialty, Market Access, Product Release, Provider, Payer

Radar On Market Access: Does New Medicare Plan Finder Make Part D Plans Tougher to Parse?

Posted by Leslie Small on Oct 1, 2019

Some Medicare experts are expressing concern and frustration about changes to the Medicare Plan Finder that may make it more difficult for beneficiaries to find the best Part D plan for their unique circumstances, AIS Health reported.

For example, the version of the new plan finder that CMS debuted does not include the ability to sort Part D plans based on a beneficiary's total out-of-pocket drug costs (including plan premium) for the rest of the year, says Ann Kayrish, who is the National Council on Aging’s senior program manager for Medicare.
 
Read More

Topics: Industry Trends, Data & Analytics, Provider, Payer

Radar On Market Access: Industry Groups Praise OIG Report on Medicare Part D Rebates

Posted by Lauren Flynn Kelly on Sep 26, 2019

Industry trade groups that would like rebates preserved in the Medicare Part D purchasing system were thrilled to see a Sept. 13 report from the HHS Office of Inspector General that they viewed as dispelling the oft-purported "myth" that rebates are responsible for high drug prices, AIS Health reported.

The report examining the more than 1,510 brand-name drugs with Part D reimbursement and rebates between 2011 and 2015 found that rebates did not always go up when unit reimbursement grew.
 
Read More

Topics: Industry Trends, Data & Analytics, Provider, Payer

Radar On Market Access: Health Plans Are Hesitant to Add New Narcolepsy Drugs to Formularies

Posted by Jane Anderson on Sep 24, 2019

Two newly approved narcolepsy medications offer novel, possibly more effective options to people for whom older medications aren't working well, but most health plans are requiring patients and providers to try generic alternatives first, AIS Health reported.

The FDA approved Jazz Pharmaceuticals' Sunosi (solriamfetol) for adults with narcolepsy or obstructive sleep apnea in March and Harmony Biosciences, LLC's Wakix (pitolisant) in August. Sunosi was launched in July, and Wakix is expected to be launched later this year

Read More

Topics: Specialty, Market Access, Product Release, Provider, Payer

Perspectives on Million-Dollar Treatments

Posted by Leslie Small on Sep 19, 2019

For large, self-insured U.S. employers, their No. 1 concern related to pharmacy benefits is how to finance treatments that come with seven-figure price tags.

That's one finding of the National Business Group on Health (NBGH) 2020 Large Employers' Health Care Strategy and Plan Design Survey, AIS Health reported. Among the 147 employer respondents, 86% said they were either concerned or very concerned about "the impact of million-dollar treatments getting approved by the FDA."
 
Read More

Topics: Industry Trends, Provider, Payer

Radar On Market Access: AML Therapy Class Has Seen Boom Over Past Couple of Years

Posted by Angela Maas on Sep 19, 2019

The FDA has approved nearly 10 therapies for acute myeloid leukemia (AML) over the past couple of years. Because most of them target a specific biomarker, it's critical that people diagnosed with the condition undergo genetic testing to determine whether they fall into a particular patient subgroup, AIS Health reported.

"Prior to two years ago, we had no new drugs for over a decade, and now we have eight new drugs approved in just the last two years, so the whole field has changed," said Daniel J. DeAngelo, M.D., Ph.D., chief, division of leukemia, institute physician, professor of medicine, Harvard Medical School, in an interview published on the website obroncology.com.
 
 
Read More

Topics: Specialty, Industry Trends, Market Access, Provider, Payer